Aurora Spine (ASG) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenues reached $4.5 million, up 10.2% year-over-year, driven by proprietary product adoption and expanded sales efforts in ambulatory surgical and pain centers.

• EBITDA/EBITDAC improved to $142,000 from $106,000 in Q2 2024, reflecting higher sales and gross margins, with a sequential increase from a Q1 2025 loss.

• Net loss was $199,000, slightly higher than $154,000 in Q2 2024, with EPS flat at $0.00 per share.

• Gross margin remained strong at 62.2%, nearly flat year-over-year and improved sequentially.

• Focus remains on minimally invasive spine procedures, new product launches, and expanding the sales team.

Financial highlights

• Total revenues were $4.5 million, up from $4.02 million in Q2 2024, a 10.2% increase year-over-year.

• Gross profit for Q2 2025 was $2.8 million, with gross margin at 62.2%.

• Operating expenses rose to $3 million, up from $2.74 million, mainly due to higher sales commissions and marketing.

• EBITDA/EBITDAC for Q2 2025 was $142,000, up from $106,000 in Q2 2024.

• Cash at quarter-end was nearly $600,000, with accounts receivable stable and collections improving.

Outlook and guidance

• Anticipates continued revenue growth through 2025, supported by new product launches and expanded sales efforts.

• Expects Hydra Arrow (Hydra A.E.R.O.) and DEXA-L launches to act as growth catalysts in the second half of 2025.

• Full commercial launch of Hydra Arrow expected in Q2 2026.